Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818 (Catequentinib) to Nivolumab in Solid Tumors

NCT04165330 is registered in ClinicalTrials.gov with Sarcoma Oncology Research Center, LLC as lead sponsor.

NCT NCT04165330
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04165330 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818 (Catequentinib) to Nivolumab in Solid Tumors
Lead sponsor
Sarcoma Oncology Research Center, LLC
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 17, 2019
Completion date
March 31, 2028
Enrollment
56 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer, small cell lung cancer, soft tissue sarcoma, solid tumor, adult